- Home
- NCL vs SBFM Comparison
NCL vs SBFM Comparison
Compare NCL & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCL | SBFM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCL | SBFM |
|---|---|---|
| Price | $0.34 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 18.1M | 45.0K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,997,205.00 | ★ $37,323,742.00 |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.24 |
| 52 Week Low | $0.10 | $1.16 |
| 52 Week High | $12.16 | $3.90 |
Technical Indicators
Market Signals| Indicator | NCL | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 30.59 |
| Support Level | $0.10 | $1.16 |
| Resistance Level | $0.49 | $1.40 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 60.90 | 28.79 |
Price Performance
Historical ComparisonAbout NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.